Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)

v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Total equity attributable to the shareholders'
Common Stock
Additional paid in capital
Retained earnings
Accumulated other comprehensive loss
Non- controlling interest
Beginning balance (in shares) at Mar. 31, 2025     60,993,949        
Equity, beginning of period at Mar. 31, 2025 $ 1,224,564 $ 1,224,447 $ 61 $ 246,610 $ 1,078,172 $ (100,396) $ 117
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Sale of Comrun LLP (117)           (117)
Forfeited stock based compensation (in shares)     (82,906)        
Stock based compensation (in shares)     248,888        
Stock based compensation 38,550 38,550   38,550      
Foreign currency translation adjustments, net of tax effect (108,640) (108,640)       (108,640)  
Other comprehensive income (loss) 14,585 14,585       14,585  
Net income 73,064 73,064     73,064    
Ending balance (in shares) at Sep. 30, 2025     61,159,931        
Equity, end of period at Sep. 30, 2025 1,242,006 1,242,006 $ 61 285,160 1,151,236 (194,451) 0
Beginning balance (in shares) at Jun. 30, 2025     61,205,640        
Equity, beginning of period at Jun. 30, 2025 1,246,225 1,246,225 $ 61 269,664 1,115,528 (139,028) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Forfeited stock based compensation (in shares)     (82,906)        
Stock based compensation (in shares)     37,197        
Stock based compensation 15,496 15,496   15,496      
Foreign currency translation adjustments, net of tax effect (66,836) (66,836)       (66,836)  
Other comprehensive income (loss) 11,413 11,413       11,413  
Net income 35,708 35,708     35,708    
Ending balance (in shares) at Sep. 30, 2025     61,159,931        
Equity, end of period at Sep. 30, 2025 $ 1,242,006 1,242,006 $ 61 285,160 1,151,236 (194,451) 0
Beginning balance (in shares) at Mar. 31, 2026 61,292,581   61,292,581        
Equity, beginning of period at Mar. 31, 2026 $ 1,489,279 1,489,279 $ 61 314,657 1,231,500 (56,939) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Purchase of Bilim 404           404
Forfeited stock based compensation (in shares)     (15,450)        
Contribution of shareholder 231 231   231      
Stock based compensation (in shares)     136,179        
Stock based compensation 30,592 30,592   30,592      
Private placement (in shares)     2,374,356        
Private placement 300,000 300,000 $ 2 299,998      
Foreign currency translation adjustments, net of tax effect 135,549 135,549       135,549  
Other comprehensive income (loss) (18,270) (18,270)       (18,270)  
Net income $ 77,724 78,185     78,185   (461)
Ending balance (in shares) at Sep. 30, 2026 63,787,666   63,787,666        
Equity, end of period at Sep. 30, 2026 $ 2,015,509 2,015,566 $ 63 645,478 1,309,685 60,340 (57)
Beginning balance (in shares) at Jun. 30, 2026     61,428,760        
Equity, beginning of period at Jun. 30, 2026 1,535,276 1,535,276 $ 61 338,123 1,263,160 (66,068) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Purchase of Bilim 404           404
Forfeited stock based compensation (in shares)     (15,450)        
Stock based compensation 7,357 7,357   7,357      
Private placement (in shares)     2,374,356        
Private placement 300,000 300,000 $ 2 299,998      
Foreign currency translation adjustments, net of tax effect 139,949 139,949       139,949  
Other comprehensive income (loss) (13,541) (13,541)       (13,541)  
Net income $ 46,064 46,525     46,525   (461)
Ending balance (in shares) at Sep. 30, 2026 63,787,666   63,787,666        
Equity, end of period at Sep. 30, 2026 $ 2,015,509 $ 2,015,566 $ 63 $ 645,478 $ 1,309,685 $ 60,340 $ (57)